Alnylam announces preliminary* fourth quarter and full year 2022 global net product revenues and provides additional updates

Cambridge, mass.--( business wire )--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today announced its preliminary* fourth quarter and full year 2022 global net product revenues for onpattro, amvuttra, givlaari, and oxlumo and provided additional updates on the products' commercial launches.

ALNY Ratings Summary

ALNY Quant Ranking